Results 341 to 350 of about 197,632 (380)

Spatiotemporal crosstalk among mitochondrial dynamics, NLRP3 inflammasome activation, and histone lactylation drives <i>α</i>-synuclein pathology in prodromal Parkinson's disease. [PDF]

Front Cell Neurosci
Lv P, Chen X, Liu S, Zhang Y, Bai Y, Wang S, Wang Y.   +6 more
europepmc   +1 more source

Anti‐Neuroinflammatory and Anti‐Inflammatory Effects of the NLRP3 Inhibitor NT‐0796 in Subjects with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Inhibition of Nod‐like receptor protein 3 (NLRP3) inflammasome within the central nervous system (CNS) is a promising therapeutic target for the treatment of Parkinson's disease (PD). Objectives This phase 1b open‐label study was conducted in elderly healthy volunteers (HV) and PD patients.
Nicholas Clarke, Peter Thornton, Valérie Reader, Nicola Lindsay, Zsofia Digby, Bianca Mullen, Michelle Gorman, Eric Jacobson, Grant Langdon, Hilary Johnstone, Alistair Wheeler, Alan P. Watt   +11 more
wiley   +1 more source

Beyond apoptosis: Exploring necroptosis, ferroptosis, and pyroptosis in sevoflurane- and isoflurane-associated PNDs. [PDF]

IBRO Neurosci Rep
Sun H, Cai R, Zhao M, Shan Y, Ma K, Qian M.   +5 more
europepmc   +1 more source

Systematic Review with Meta‐Analysis of Biofluid Markers for Huntington's Disease

Movement Disorders, EarlyView.
Eight Huntington's Disease Biofluid Markers show Meta‐Analytic Significance Across HD‐ISS Stages. Meta‐analyses were conducted for two types of biomarkers: Different from demographically‐matched healthy controls and *Showing change over time. Abstract Primary therapeutic objectives for Huntington's disease (HD) necessitate continued therapy for a long ...
Jane S. Paulsen, Natalie A. Bovin, Jordan D. Clemsen, Alexander Weiss, Abigail M. Key, Monica L. Janz, Alex Pinto, Deven K. Burks, Henrik Zetterberg, Kathleen M. Shannon   +9 more
wiley   +1 more source

The regulatory effects of luteolin, calycosin, and formononetin on the NLRP3/IL-33/ILC2s axis in the treatment of allergic rhinitis: mechanistic analysis and therapeutic potential. [PDF]

Front Pharmacol
Jia M, Lei X, Jiang F, Li D.
europepmc   +1 more source

Targeting the NLRP3-ROS Axis: Disrupting the Oxidative-Inflammatory Vicious Cycle in Intracerebral Hemorrhage. [PDF]

J Inflamm Res
Cao L, Pi W, Zhang Y, Zheng C, Yong VW, Xue M.   +5 more
europepmc   +1 more source

Adipocyte FMO3-derived TMAO induces WAT dysfunction and metabolic disorders by promoting inflammasome activation in ageing. [PDF]

Nat Commun
Ganapathy T, Yuan J, Ho MY, Wu KK, Hoque MM, Wang B, Li X, Wang K, Wabitsch M, Feng X, Niu Y, Long K, Lian Q, Zhu Y, Cheng KK.   +14 more
europepmc   +1 more source

Exosomes derived from mesenchymal stem cells repair ovarian function by suppressing NLRP3-mediated pyroptosis in cyclophosphamide-induced premature ovarian failure. [PDF]

J Ovarian Res
Cui X, Li H, Huang X, Xue T, Wang S, Zhu X, Jing X.   +6 more
europepmc   +1 more source

From mechanisms to markers: role of pyroptosis in revolutionizing thyroid cancer care. [PDF]

Cell Death Discov
Wang N, Chen Y, Luo G, Luo D.
europepmc   +1 more source